Chekalina N. I.

RESVERATROL MORE SIGNIFICANTLY THAN QUERCETIN IMPROVES CENTRAL HEMODYNAMICS IN PATIENTS WITH ISCHEMIC HEART DISEASE

---

Show/Download

About the author:

Chekalina N. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The leading cause of death in the world remains coronary heart disease (IHD), despite the numerous treatments being developed. Therefore, the search for new effective methods of treatment of IHD is extremely relevant. One of the pathogenetic mechanisms for the progression of atherosclerosis, which is the morphological basis of coronary heart disease, is chronic systemic inflammation. Anti-inflammatory activity at different levels of proinflammatory signaling have polyphenols of plant origin. The purpose of the work is to assess the impact of polyphenols of respheratrol and quercetin on the indicators of central hemodynamics in patients with IHD. A prospective open randomized controlled trial was conducted with the participation of 230 people with IHD, I-II functional class (FC), with heart failure not higher than II FC. After assessing hemodynamics, according to echocardiography (echo), patients are randomized into 2 groups of study and a comparison group. Along with the basic therapy of ICH, the study group And assigned 100 mg of resveratrol per day, group II –120 mg of quercetin per day. After 2 months, the results of echo were evaluated. In patients with IHD, signs of diastolic dysfunction by type And by type – relaxation disorder have been identified. The presence of heart failure by diastolic type was confirmed by the the left ventricle isovolumetric relaxation time and the left ventricle deceleration time, and the size of the left atrium. Systolic function in the vast majority of patients corresponded to the limits of the norm, but was significantly less than in the group of healthy individuals. Under the influence of both polyphenols, more significantly than with the use of standard therapy, the systolic and diastolic functions of LV have improved, with the advantage of resveratrol. The use of resveratrol and quercetin in complex therapy of patients with IHD had a positive effect on the central hemodynamics, especially on the diastolic function of the left ventricle, with the advantage of resveratrol efficiency, which makes it possible to recommend it for wide use in the treatment of IHD.

Tags:

Bibliography:

1. Ievropeiska baza danykh statystychnoi informatsii «Zdorovia dlia vsikh». Dostupno: http://medstat.gov.ua/ukr/ normdoc.html. [in Ukrainian].
2. Kovalenko VM, Lutai MI, Sirenko YuM, Sychov OS. Sertsevo-sudynni zakhvoriuvannia: klasyfikatsiia, standarty diahnostyky ta likuvannia. Kiev: Morion; 2019. 239 s. [in Ukrainian].
3. Sakhanda IV, Nehoda TS, Siatynia ML. Faktory ryzyku vynyknennia, struktura i dynamika rozvytku sertsevo-sudynnoi zakhvoriuvanosti naselennia Ukrainy. Liky Ukrainy. 2015;4(25):116-8. [in Ukrainian].
4. Kovalenko VM. Stres i sertsevo-sudynni zakhvoriuvannia i umovakh voiennoho stanu. Kyiv; 2022. 267 s. [in Ukrainian].
5. Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathol Int. 2022 Mar;72(3):151-160.
6. Hedrick CC. Lymphocytes in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015;35(2):253-7.
7. Brunetti ND, Correale M, Pellegrino PL, Munno I, Gennarj LD, Cuculo A, et al. Early inflammatory cytokine response: A direct comparison between spontaneous coronary plaque destabilization vs angioplasty induced. Atherosclerosis. 2014;236(2):456-60.
8. Sobhani M, Farzaei MH, Kiani S, Khodarahmi R. Pharmaceutical Science Immunomodulatory; Anti-inflammatory/antioxidant Effects of Polyphenols: A Comparative Review on the Parental Compounds and Their Metabolites. Food Reviews International. 2021;37(3):759-811.
9. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Stabilna ishemichna khvoroba sertsia. Novyny medytsyny i farmatsii. Kardyolohiia i revmatolohiia (tematychnyi nomer). 2016;572:27-60. [in Ukrainian].
10. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998;158(5.1):1384-7.
11. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Salvo GD, Donal E. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging. 2017;18(12):1301-10.
12. Riffenburgh RH, Gillen DL Statistics in Medicine. 4th ed. Oxford, UK: Academic Press; 2020. 795 p.
13. Hallstrem A, Pratt CM, Greene H, Huther M, Gottlieb S, A DeMaria A, et al. Relationship between heart failure, ejection fraction, arrhythmia supression and mortality: analysis of the cardiac arrhythmia suppression trial. JACC. 1995;13(1):1250-7.
14. Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis. The heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021 May 14;128(10):1451-1467.
15. Schulman IH, Raij L. The angiotensin II type 2 receptor: what is its clinical significance. Curr. Hypertens. REP. 2008;10:188-93.
16. Frangogiannis NG. The inflammatory response in myocardial injury, repair and remodelin. Nat. Rev. Cardiol. 2014;11(5):255-65.
17. Christa A, Bekkeringd S, Latza E, Riksen NP. Long-term activation of the innate immune system in atherosclerosis. Seminars in Immunology. 2016;28(4):384-93.
18. Chekalina, NI, Shut SV, Trybrat TA, Burmak YuG, Petrov YeYe, Manusha YI, et al. Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiadomosci lekarskie. 2017;70(4):707-11.
19. Chekalina NI, Kazakov YM, Mamontova TV, Vesnina LE, Kaidashev IP. Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor α in patients with coronary artery disease. Wiadomosci lekarskie. 2016;69(3):475-9.
20. Parkhomenko AN, Kozhukhov SN. Rezultatы otkrыtoho randomyzyrovannoho yssledovanyia po yzuchenyiu perenosymosty y эffektyvnosty preparata Korvytyn u patsyentov s zastoinoi serdechnoi nedostatochnostiu y systolycheskoi dysfunktsyei levoho zheludochka. Ukrainskyi. med. chasopys. 2014;4(102):71-6. [in Ukrainian].
21. Sheng R, Gu ZL, Xie ML. Epigallocatechin gallate, the major component of polyphenols in green tea, inhibits telomere attrition mediated cardiomyocyte apoptosis in cardiac hypertrophy. Int. J. Cardiol. 2011;162:199-209.
22. Singh NP, Singh UP, Hegde VL, Guan H, Hofseth L, Nagarkatti M, et al. Resveratrol (trans-3,5,4’-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-κB. Mol. Nutr. Food. RES. 2011;55(8):1207-18.
23. Das S, Fraga CG, Das DK. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NfkappaB. Free radical research. 2006;40(10):1066-75.
24. Olson ER, Nougle JE, Zhang X, Bomser JA, Meszaros JG. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am. J. Physiol. Heart. Circ. Physiol. 2005;288:1131-8.
25. Andriantsitohaina R, Auger C, Chataigneau Т. Molecular mechanisms of the cardiovascular protective effects of polyphenols. BR. J Nutr. 2012;108(9):1532-49.
26. Voskresensky ON, Zhutaev IA, Bobyrev VN, Bezugly YuV. The antioxidant system, ontogenesis and ageing. Voprosy Meditsinskoj Khimii. 1982;28(1):14-27.
27. Kaidashev IP. Aktyvatsiia NF-kB pry metabolichnomu syndromi. Fiziol. zhurnal. 2012;58(1):93-101. [in Ukrainian].

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 3, 170, 304-309 pages, index UDC 613.292+615.356]:616.-021,272-005.4]12

DOI:

10.29254/2077-4214-2023-3-170-304-309